Pneumatosis Intestinalis in Lung Cancer Induced Twice by Different Drugs: Bevacizumab and Pemetrexed.

Abstract

A 72-year-old man diagnosed with stage 4 lung adenocarcinoma developed asymptomatic pneumatosis intestinalis while undergoing treatment with first-line chemotherapy, which included carboplatin, paclitaxel, and bevacizumab (BEV). He was treated conservatively. The pneumatosis recurred while the patient was undergoing treatment with the third-line chemotherapy, which included pemetrexed (PEM). His condition resolved after 4 weeks of supportive therapy. To our knowledge, this is the first case in which pneumatosis intestinalis was induced twice by two drugs in a patient with lung cancer. BEV and PEM are often administered to patients with lung cancer; thus, it should be noted that pneumatosis intestinalis may occur as an adverse event in patients treated with these drugs.

• Authors: Keiko Nunomiya, Sumito Inoue, Kento Sato, Akira Igarashi, Keiko Yamauchi, Yuki Abe, Masafumi Watanabe
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 60 Issue 13 Pg. 2109-2113 (Jul 01 2021) ISSN: 1349-7235 [Electronic] Japan
• PMID: 33551401 (Publication Type: Case Reports, Journal Article)

Chemical References

• Pharmaceutical Preparations
• Pemetrexed
• Bevacizumab

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Bevacizumab (adverse effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Neoplasm Recurrence, Local
• Pemetrexed (adverse effects)
• Pharmaceutical Preparations